Innate Pharma reports increase in annual revenue for 2012

• Revenue of 14.3 million euros including payments from Bristol-Myers Squibb and research tax credit
• Strong cash position with 32.6 million euros in cash, cash equivalents and current financial instruments as at December 31, 2012

(IFRS unaudited provisional data)

Innate Pharma SA (Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, announces revenue and other income of 14.3 million euros for the year 2012, compared to 11.7 million euros in 2011.